1. Introduction {#sec1-ijms-20-00778}
===============

Cancer is a multifaceted disease and over time, metals, metabolites, and microbes, among others, have been proven to be critically involved in the onset and progression of this disease. In particular, lung cancer (LC) is the second most prominent type of cancer in the world, the first cancer death cause \[[@B1-ijms-20-00778]\], and the five-year survival rate is only 15% \[[@B2-ijms-20-00778]\].

In relation to metals, there are two different points of view to explain their role in the organism during the carcinogenic process, because they can be considered a cause or an effect. The first one is based on the hypothesis that cancer onset and progression disturb the natural chemical form of the essential element in the metabolism. The second one considers that elements are involved in the carcinogenic process because they are a consequence of their high exposure. Moreover, metals also contribute to cancer progression and metastasis \[[@B3-ijms-20-00778],[@B4-ijms-20-00778],[@B5-ijms-20-00778],[@B6-ijms-20-00778],[@B7-ijms-20-00778]\]. On the other hand, the majority of works focus on the estimation of a deficiency state or excess and into a lesser extent in the unbalance episodes in which one element affects the function of others.

Approximately one-third of proteins need the presence of metals as cofactors to develop their function (metalloproteins), and in general, more than 50% of the proteins are influenced by metals \[[@B8-ijms-20-00778]\]. Likewise, metals are responsible for the structure or catalytic properties of proteins, and their link to a molecule is usually determined by the genome \[[@B9-ijms-20-00778]\]. Moreover, elements are essential to maintain human homeostasis and play key roles in systems biology, participating in many cellular processes. Essential metals, which are only required in trace amounts, are crucial for the function of numerous enzymes that are required for fundamental biochemical processes, and non-essential metals can alter the function of some enzymes as well \[[@B10-ijms-20-00778]\]. However, metals are also involved in numerous biological processes such as the transport of oxygen in the blood; this process is mediated by hemoglobin, which contains Fe \[[@B11-ijms-20-00778]\]. The deficiency or excess of any of these elements can lead to disease (e.g., anemia) or deleterious toxic effects, inflammation \[[@B12-ijms-20-00778]\], and cancer \[[@B13-ijms-20-00778]\]. For this reason, the levels of essential metals have to be carefully balanced, and a homeostatic state has to be maintained within the body \[[@B12-ijms-20-00778]\].

On the other hand, a number of non-essential elements can also have important implications on human health. In this way, environmental exposure to As, Cd, Pb, and Ni has carcinogenic consequences \[[@B13-ijms-20-00778]\] due to the activation of oncogenic signaling pathways \[[@B14-ijms-20-00778],[@B15-ijms-20-00778]\] and oxidative stress \[[@B13-ijms-20-00778],[@B16-ijms-20-00778],[@B17-ijms-20-00778]\]. The concentration and activity of enzymatic antioxidants are related to the concentration of elements \[[@B18-ijms-20-00778]\]. Likewise, a disturbed redox status in lung cancer patients has been proven to be related to alterations of Zn, Mn, and Cu, since they regulate the levels and activities of antioxidants (mainly enzymatic ones), and the disturbed redox status may be critical to lung carcinogenesis. In this sense, these metals are cofactors or ions stabilizing the molecular structure of superoxide dismutase (SOD), which is an endogenous antioxidant \[[@B19-ijms-20-00778]\]. Moreover, the type of biological fluid influences both alterations in the metal profile and relationships with redox status parameters \[[@B18-ijms-20-00778]\].

Although the interaction of elements has not been extensively researched, it is known that metals can influence the function of others through antagonistic or synergistic mechanisms, as is the case of the competitive interaction of Zn and Cd for many enzymes due to their very similar atomic structure \[[@B20-ijms-20-00778]\]. It has been pointed out that this interaction has dramatic effects on many zinc-containing enzymes that are involved in important biological processes leading to cancer onset \[[@B21-ijms-20-00778]\]. Another important interaction between metals that has been described in the literature in connection with lung cancer is that of Cu and Zn. Decreased Zn and elevated Cu concentrations (high Cu:Zn ratio) in serum are the most successfully used predictor variables to distinguish between lung cancer (LC) and healthy controls (HC) \[[@B18-ijms-20-00778],[@B22-ijms-20-00778],[@B23-ijms-20-00778],[@B24-ijms-20-00778]\]. Cu is an essential trace element in the diet, and has a pivotal role in enzymes related to oxidative metabolism, since it is needed for the interconversion of cupric and cuprous ions \[[@B25-ijms-20-00778]\], but also contributes to the generation of free radicals \[[@B25-ijms-20-00778]\]. Zn is a constituent of over 300 enzymes that play vital roles in gene expression \[[@B26-ijms-20-00778]\]. Increased levels of Cu in serum of LC have been related to tumor progression through angiogenesis (the formation of new capillaries from existing blood vessels) to meet the nutritional requirements of a growing tumor \[[@B27-ijms-20-00778],[@B28-ijms-20-00778]\]. Decreased levels of Zn have been related to alterations in the cell cycle and apoptosis \[[@B29-ijms-20-00778],[@B30-ijms-20-00778]\], and the inability to block the further absorption of Cu \[[@B31-ijms-20-00778]\]. Low serum Zn concentrations may affect protein synthesis and delay the repair processes of the body because of possible influences of depleting Zn-binding protein and metalloenzymes \[[@B32-ijms-20-00778]\]. Moreover, it seems to be correlated with lymphocyte dysfunction \[[@B33-ijms-20-00778]\]. Moreover, Zn^2+^ acts a cofactor for histone deacetylases (HDACs), which are a family of enzymes that are responsible for protein acetylation and deacetylation. An anomalous histone acetylation, and consequently an alteration in the expression of HDACs, is related to cancer \[[@B34-ijms-20-00778],[@B35-ijms-20-00778],[@B36-ijms-20-00778],[@B37-ijms-20-00778],[@B38-ijms-20-00778],[@B39-ijms-20-00778]\] Likewise, an overexpression of HDAC1 and HDAC2 has been found in LC \[[@B40-ijms-20-00778]\], and HDAC8 knockdown leads to the inhibition of cell proliferation in lung and other types of cancer \[[@B41-ijms-20-00778]\]. Thus, an upregulation in concentrations of Zn^2+^ could be related to perturbation in the action of HDACs.

Synergistic interactions have also been described as in the case of Zn and Se, whose depressed levels seem to be involved in carcinogenesis by increasing DNA damage and oxidative stress, decreasing antioxidant defense capacity, inhibiting DNA repair mechanisms, and declining immune function \[[@B42-ijms-20-00778],[@B43-ijms-20-00778]\]. The chemopreventive character of Se for most cancers has been extensively reviewed, mostly in relation to its antioxidative role via glutathione peroxidase (GSH-Px) \[[@B44-ijms-20-00778]\]. It seems that the depressed levels of Se in serum from LC patients might be a consequence of increased uptake by tumoral tissues in response to oxidative stress mediated by free radicals, since GSH-Px is required by the tumor tissues to prevent the damage caused by free radicals. Se is also involved in inhibiting angiogenesis \[[@B45-ijms-20-00778]\] and enhancing the immune response \[[@B46-ijms-20-00778]\], and is a well-documented antagonist against toxic metals \[[@B47-ijms-20-00778]\]. Se also controls the unnecessary proliferation of cells \[[@B48-ijms-20-00778]\] and inhibits the activation of certain transcription factors \[[@B49-ijms-20-00778]\]. Mn superoxide dismutase (Mn-SOD), as a single superoxide radical scavenger in mitochondria, may have a key role in preventing cells as an antioxidant and tumor suppressor \[[@B50-ijms-20-00778]\]. In the lungs, Mn-SOD is considered to be of critical importance for antioxidant defense \[[@B51-ijms-20-00778]\]. A number of studies have defined associations between the Mn-SOD Ala16Val polymorphism and different cancer types \[[@B52-ijms-20-00778],[@B53-ijms-20-00778],[@B54-ijms-20-00778]\]. It has been stated that there is a disruption in Mn homeostasis during cancer development, resulting in mobility from one compartment to other \[[@B18-ijms-20-00778]\].

Ni is a carcinogenic agent that has been implicated as a pulmonary carcinogen in tobacco smoke \[[@B55-ijms-20-00778]\]. Nickel causes oxidative DNA damage. \[[@B56-ijms-20-00778]\]. Cr is associated with glucose and lipid metabolism, protein synthesis, and other important physiological functions \[[@B57-ijms-20-00778]\]. On the other hand, the hexavalent form of chromium and its containing compounds are well-established lung carcinogens. Chronic exposure of the normal human epithelial cells is able to induce malignant cell transformation, which is the first stage of metal carcinogenesis \[[@B58-ijms-20-00778]\]. Some authors have reported on the anticancer properties of V, and showed that the complexes of these metals are the new metal-based drugs that are used in the treatment of several cancers, such as lung cancer \[[@B59-ijms-20-00778]\]. Other authors have demonstrated the influence of vanadium compounds in the cytotoxicity of some ligands in human lung cancer-cultured cells \[[@B60-ijms-20-00778]\].

The "metallome" can be defined as the ensemble of all the biomolecules in a system, which bind a given metal ion or an inorganic element, or are affected by that element. A number of subsets of a metallome can then be defined based on the nature of the biomolecules interacting with the metal ions and the inorganic elements in general \[[@B61-ijms-20-00778]\]. Williams defined the "metallome" as the distribution of elements, or concentration at equilibrium of free metallic ions or free elements in a cellular compartment, cell, or organism \[[@B62-ijms-20-00778]\]; the metallome is related to the identity and/or quantity of metals/metalloids and their chemical species \[[@B8-ijms-20-00778],[@B63-ijms-20-00778],[@B64-ijms-20-00778]\]. In this way, metallomics considers that the identification of a metal cofactor in a protein is critical to finally assigning its function as well as placing it in the context of known cellular pathways \[[@B65-ijms-20-00778],[@B66-ijms-20-00778]\]. In metallomics, metal or metalloids are used as tags or heteroatomic markers to measure metallomolecules in complex matrices, usually by means of a chromatographic separation step coupled to inductively coupled plasma mass spectrometry (ICP-MS) \[[@B67-ijms-20-00778],[@B68-ijms-20-00778],[@B69-ijms-20-00778]\]. On the other hand, considering that chemical species can be defined as "the specific forms of an element defined to isotopic composition, electronic, or oxidation state and/or complex or molecular structure" \[[@B70-ijms-20-00778]\], metallomics, metal-metabolomics, and chemical speciation are completely imbricated.

2. Metal Dyshomeostasis in Lung Cancer: Biofluids and Tissues {#sec2-ijms-20-00778}
=============================================================

The relationship between metal exposure and lung cancer (LC) has been deeply studied, especially in occupational medicine and environmental studies. The use of metals for diagnosis is more scarce, but several authors have classified lung cancer patients and healthy people using metals content in tumor tissues \[[@B71-ijms-20-00778],[@B72-ijms-20-00778]\], serum, hair \[[@B24-ijms-20-00778],[@B73-ijms-20-00778]\], urine \[[@B74-ijms-20-00778]\], and bronchoalveolar lavage fluid (BALF) \[[@B75-ijms-20-00778]\], because they found statistically significant differences from the normal distribution of elements for the diagnosis of LC. Then, in the literature, it is possible to find levels of essential and non-essential elements in different biofluids and tissues of lung cancer (LC) patients, for example in plasma \[[@B76-ijms-20-00778],[@B77-ijms-20-00778]\], serum \[[@B18-ijms-20-00778],[@B24-ijms-20-00778],[@B42-ijms-20-00778],[@B75-ijms-20-00778],[@B78-ijms-20-00778]\], urine \[[@B74-ijms-20-00778],[@B75-ijms-20-00778],[@B79-ijms-20-00778]\], pleural effusion \[[@B80-ijms-20-00778]\], or hair \[[@B24-ijms-20-00778],[@B73-ijms-20-00778]\], and recently in bronchoalveolar lavage fluid (BALF) for the first time \[[@B75-ijms-20-00778]\]. [Table 1](#ijms-20-00778-t001){ref-type="table"} has a collection of the typical concentrations in tissues and biofluids of LC patients and HC that can be found in the literature.

It is well-known that the use of biomarkers such as metals in hair, nails, blood (serum, plasma, or whole blood) or urine can be used to detect abnormal levels in the human body as a consequence of acute (biofluids) or long-term exposure (hair and nails). The type of biosample used in the study is also important, because metal profiles and their relationships with redox status parameters are different \[[@B18-ijms-20-00778]\]. Likewise, serum seems to be better for Cu and whole blood for Mn, while in the case of Zn, it is not relevant. For the determination of the relationships between trace elements and redox status parameters, authors have recommended the use of different samples \[[@B18-ijms-20-00778]\]. On the other hand, there are several papers describing the analysis of metals in bronchoalveolar lavage fluid \[[@B83-ijms-20-00778],[@B84-ijms-20-00778]\], but only one is related to lung cancer patients \[[@B75-ijms-20-00778]\].

BALF is obtained during the exploratory study of patients with lung diseases, and provides constituents' information on the cellular and biochemical epithelial surface of the lower respiratory tract through the instillation and later aspiration of liquid in one or more lung segments. It is estimated that BALF samples take a million cells (1% of the lung surface) to yield about one ml of pulmonary secretions in the actual total recovered liquid \[[@B85-ijms-20-00778]\]. Since BALF is in close interaction with lung tissue, it is a more representative sample of lung status than other biofluids such as blood or urine.

In serum, decreased Zn and elevated Cu concentrations (high Cu:Zn ratio) are the most common biomarkers of LC \[[@B18-ijms-20-00778],[@B24-ijms-20-00778],[@B42-ijms-20-00778],[@B81-ijms-20-00778],[@B82-ijms-20-00778],[@B86-ijms-20-00778],[@B87-ijms-20-00778]\]. The concentration of Cu \[[@B88-ijms-20-00778]\] and the Cu:Zn ratio \[[@B22-ijms-20-00778],[@B77-ijms-20-00778]\] have also been demonstrated to be increased in the plasma of LC patients. The concentration of copper is related to the cancer state and localization, and is primarily found in serum (95% as part of the oxidative enzyme ceruloplasmin, and the remainder is loosely bound to albumin) \[[@B89-ijms-20-00778]\]. On the other hand, low serum levels of Zn are usually correlated with high levels of Zn in tumor autopsy, which suggest that the metabolic requirements of this element by LC cells are taken from serum \[[@B90-ijms-20-00778]\]. Ren et al. also found that Cu, Cr, P, and Zn were found to be significantly different between LC and HC \[[@B24-ijms-20-00778]\]. As can be seen in [Table 1](#ijms-20-00778-t001){ref-type="table"}, there are some contradictory results regarding the decreased concentration of Zn, which in some papers in the literature have been found to be increased in serum, urine, and BALF. However, the most important fact is that the Cu:Zn ratio is increased.

Lin et al. \[[@B76-ijms-20-00778]\] found higher levels of Mn in serum from the LC group, but there are contradictory results \[[@B18-ijms-20-00778],[@B42-ijms-20-00778]\]. Among other elements, increased concentrations of Ti, Ni, and Cu, but lowered concentrations of V, Cr, Mn, Fe, Co, Zn, Se, and Br have been determined in the serum of LC patients \[[@B42-ijms-20-00778]\].

However, other studies revealed higher concentrations of V in the serum of LC patients \[[@B75-ijms-20-00778]\]. Finally, Cr is another element that is usually increased in the serum of LC patients \[[@B24-ijms-20-00778],[@B75-ijms-20-00778],[@B76-ijms-20-00778]\].

The determination of 11 elements in the BALF of LC patients demonstrated that increased levels of Mn can be used as a biomarker, since it showed a VIP (Variable Importance on the Projection) value of 1.29, a fold change of 1.5, a p-value of 0.003, and an AUC (Area Under the Curve) value of 0.75 \[[@B75-ijms-20-00778]\]. Other authors also reported decreased levels of manganese in BALF from patients with diffuse lung diseases \[[@B91-ijms-20-00778]\] or calves with mycoplasma bronchopneumonia \[[@B92-ijms-20-00778]\]. On the other hand, the determinations of metals in the pleural effusion (PE) of smokers with lung cancer revealed lower Zn concentrations \[[@B80-ijms-20-00778]\]. On the other hand, an adequate Zn intake has been associated with a decreased risk of smoking-associated obstructive lung disorders \[[@B93-ijms-20-00778]\]. Moreover, low Zn levels may result in high glucose levels in the PE of smokers with LC due to a decreased glucose metabolism \[[@B80-ijms-20-00778]\].

In urine, Tan et al. demonstrated that Fe, Mn, and Al were significantly decreased in the urine of LC patients, while Se, Ni, Cu, Zn, Cd, and Cr increased \[[@B74-ijms-20-00778],[@B79-ijms-20-00778]\]. Voyatzoglou et al. \[[@B23-ijms-20-00778]\] reported that patients with lung cancer and hyperzincuria had more widespread disease and a shorter life expectancy compared with patients with normal urinary zinc levels. On the other hand, a recent study revealed that the concentration of Cd, which is a recognized carcinogen, was increased in the urine of LC patients \[[@B75-ijms-20-00778]\].

The concentration of elements has also been determined in the hair of LC patients versus HC, showing that the levels of Zn, Mg, Fe, and Se were higher in LC patients, while Ca, Sn, and Na were lower \[[@B73-ijms-20-00778]\]. Other authors also described that Al, B, Cr, P, and Sr were significant variables for the classification between LC versus HC \[[@B24-ijms-20-00778]\].

The study of metals in the tumor tissues of lung cancer patients showed decreased Fe and Mn levels in malignant versus normal lung tissue giving the best classification. These two elements correctly identified 10 of the 13 malignant tissues with an accuracy of 77%. The inclusion of other elements, especially Cu, but also others such as Ca, V, Fe, Cu, Zn, Se, Br, Sr, Hg, As, and Mo resulted in the correct grouping of 100% of samples \[[@B71-ijms-20-00778]\]. Other authors found that the concentrations of P, Ti, and Pb increased in LC patients versus HC, while the levels of Ca, Fe, Cu, and Zn decreased \[[@B72-ijms-20-00778]\]. Other authors reported that the levels of studied elements showed a trend of accumulation in cancer tissues \[[@B88-ijms-20-00778]\]. Moreover, several authors found differences between concentrations of several metals according to sex \[[@B72-ijms-20-00778]\] and age \[[@B94-ijms-20-00778]\] in the tumor tissues of LC patients.

In relation with the analytical techniques used in these studies, most elemental determinations in biofluids have been performed by atomic absorption spectroscopy (AAS) \[[@B81-ijms-20-00778],[@B82-ijms-20-00778],[@B83-ijms-20-00778],[@B87-ijms-20-00778],[@B91-ijms-20-00778]\], particle-induced X-ray emission \[[@B95-ijms-20-00778]\], energy-dispersive X-ray fluorescence \[[@B96-ijms-20-00778]\], inductively coupled plasma atomic emission spectroscopy (ICP-AES) \[[@B24-ijms-20-00778],[@B74-ijms-20-00778],[@B79-ijms-20-00778]\], or inductively coupled plasma mass spectrometry (ICP-MS) \[[@B73-ijms-20-00778],[@B76-ijms-20-00778],[@B77-ijms-20-00778],[@B80-ijms-20-00778],[@B84-ijms-20-00778]\]. The main advantage of using an ICP-MS equipped with a triple quadrupole is the elimination of interferences by operating in either standard single quadrupole (SQ) mode or triple quadrupole (ICP-QQQ-MS). For instance, in the case of selenium, great advantages can be obtained with an ICP-QQQ-MS, because the signal of ^80^Se in oxygen mode (^96^SeO^+^) would overlap with signals such as ^96^Zr^+^, ^96^Mo^+^, or ^96^Ru^+^ in a conventional ICP-MS, but with the ICP-QQQ-MS, this drawback is overcome through eliminating these elements in the first quadrupole \[[@B75-ijms-20-00778]\].

3. Inter-Element Ratios and Correlations as Biomarkers of Lung Cancer {#sec3-ijms-20-00778}
=====================================================================

The importance of metal homeostasis and metals interactions in biology has been extensively investigated \[[@B47-ijms-20-00778]\]. Regarding lung cancer disease, the majorities of works have focused on the estimation of a deficiency state or excess, and have examined the unbalanced episodes in which the excess of one element affects the function of other to a lesser extent. Although the interplay of elements is rarely reported, it is possible to find two different ways to evaluate the interactions of metals based on the metals' ratios and correlation coefficients. As commented before, the Cu:Zn ratio has been demonstrated to be increased in the serum \[[@B18-ijms-20-00778],[@B23-ijms-20-00778],[@B24-ijms-20-00778],[@B42-ijms-20-00778],[@B81-ijms-20-00778],[@B82-ijms-20-00778],[@B86-ijms-20-00778],[@B87-ijms-20-00778]\], plasma \[[@B22-ijms-20-00778],[@B77-ijms-20-00778]\], whole blood \[[@B18-ijms-20-00778]\], urine \[[@B23-ijms-20-00778]\], hair \[[@B24-ijms-20-00778]\], and pleural effusion \[[@B80-ijms-20-00778]\] of lung cancer patients against healthy controls.

A recent study of our group demonstrated that the ratios between elements were important biomarkers for lung cancer disease, including: V/Mn, V/Pb, V/Zn, Cr/Pb in serum, Cr/Cd, Mn/Cd, V/Cd, Co/Cd, Cd/Pb in urine and V/Cu in BALF. These ratios reflect the dyshomeostasis of metals that takes place. Taken into account that cancerous and normal tissues differ significantly in their cell composition, other authors measured for each metal the ratio to K, since it is the most abundant intracellular cation \[[@B88-ijms-20-00778]\]. The results showed that the Zn/K ratio was reduced in LC and HC, whereas Cu/K slightly increased \[[@B88-ijms-20-00778]\]. The ratio between Cd and Zn has also been found to be different between smokers and nonsmokers, and it is also different among smokers for several different diseases and cancers \[[@B97-ijms-20-00778]\].

On the other hand, several metals are correlated to others, suggesting also the existence of an interconnected homeostasis in lung cancer \[[@B75-ijms-20-00778]\], as can be seen in [Table 2](#ijms-20-00778-t002){ref-type="table"}. In this way, selenium is positively correlated with zinc in BALF samples of LC. The antioxidant properties of selenium are well-known, and alterations of this element can be related to oxidative stress. In this work, selenium is positively correlated with zinc in BALF samples, which is implicated in glucometabolic disorders \[[@B98-ijms-20-00778]\]. Cobalt and copper are also positively correlated in BALF. The function of cobalt in the body is to be a cofactor of vitamin B12, but in the form of labile ions, it is able to generate reactive oxygen species, such as copper and iron \[[@B99-ijms-20-00778]\].

4. Selenometabolites and Selenoproteins and Their Role in Lung Cancer {#sec4-ijms-20-00778}
=====================================================================

One of the most known elements for its beneficial effects on health and antagonistic protective action against many pollutants is selenium. However, selenium is essential only in a narrow range of concentrations, and the chemical form also determines its essentiality/toxicity. The active center of selenoproteins (with selenocysteinyl residues) such as glutathione peroxidase and other selenoenzymes is (--SeH), but selenium can also be present in the living body as selenium-containing proteins (with selenomethionyl residues, ie selenoalbumin), inorganic selenium, selenoamino acids, and methylated selenium \[[@B100-ijms-20-00778]\]. The selenium species that is most abundant in the bloodstream is selenoprotein P (SeP), and its concentration is a good indicator of Se status in humans, while extracellular glutathione peroxidase (eGPx) is a complementary marker of selenium status in several clinical studies \[[@B101-ijms-20-00778]\]. Moreover, Se-proteins are interrelated, because Se bound to albumin (SeAlb) is assumed to be transported to the liver for the new synthesis of SeP and GPx, which are then released into the bloodstream. The concentration of selenium in human serum is about 90 ng·g^-1^, and this elements occurs as SeP \> Selenoalbumin (SeAlb) \> GPx \> SeO~3~^2−^ \[[@B102-ijms-20-00778]\]. As previously commented, selenium is part of the enzyme glutathione peroxidase (GPx), which is considered the main agent against free radicals, as an anticancer, and inhibits the toxicity of some xenobiotics \[[@B103-ijms-20-00778]\]. Until now, only 25 selenoproteins are known in humans, including four types of glutathione peroxidase (GPX1, GPX2, GPX3, and GPX4) and two thioredoxin reductases (TXNRD1, TXNRD2), but the function of many others is still unknown \[[@B104-ijms-20-00778]\].

Selenium has been studied previously in relation to cancer from several points of view. On the one hand, it has been shown that there is a decrease in the risk of lung cancer in populations where selenium levels are high \[[@B105-ijms-20-00778]\]. To this end, selenium levels in plasma samples from 372 lung cancer patients were determined by SeP determination using the ELISA method \[[@B105-ijms-20-00778]\]. In another study, serum selenium levels were determined in 95 patients with lung cancer and the genotypes of four selenoprotein genes (GPX1, GPX4, TXNRD2, and SEP15) were determined, demonstrating that a selenium level less than 60 μg·L^−1^ is associated with a higher risk of lung cancer \[[@B106-ijms-20-00778]\].

On the other hand, the chemopreventive character of selenium against cancer has been studied. In this way, it has been shown that selenium supplements reduce the mortality caused by several types of cancer, including lung cancer \[[@B107-ijms-20-00778]\]. The molecular mechanism is not completely known, although different biological and biochemical processes have been identified \[[@B108-ijms-20-00778]\], demonstrating that the effects observed at the molecular, cellular, and systemic levels include the expression of genes and the direct alteration of proteins \[[@B109-ijms-20-00778]\]. The effects of selenium depend on its concentration, since low concentrations are absolutely necessary for cell growth, but moderate to high concentrations inhibit it. This inhibition of growth is tumor-specific, and selenium induces apoptosis in malignant cells at concentrations that do not affect the viability of normal cells \[[@B110-ijms-20-00778]\]. Selenium species can affect carcinogenesis in different stages depending on the chemical species of selenium that is administered.

Several studies have suggested that polymorphisms in the selenoprotein gene of 15 kDa (SEP15) can alter the interaction of selenium with this protein, which is associated with an increase in susceptibility to various types of cancer \[[@B111-ijms-20-00778]\], including LC \[[@B112-ijms-20-00778]\]. The 15-kDa selenoprotein (SEP15) and other members of the thioredoxin family \[[@B113-ijms-20-00778]\] are a type of catalytic agent that can regulate cellular redox reaction and reduce accumulated oxidative stress, which correlates with cell death and oncogenesis \[[@B114-ijms-20-00778]\]. Finally, the relationship between the CASP8, MMP1, IL10, and SEPS1 genes and the risk of non-small cell lung cancer have also been demonstrated \[[@B115-ijms-20-00778]\].

5. Chemical Species, Metal-Metabolites, and Metalloproteins {#sec5-ijms-20-00778}
===========================================================

It is well-known that the chemical form of an element determines its toxicity and biological activity, as well as its mobility across different biological compartments. On the other hand, metallobiomolecules play key roles in the onset and progression of several diseases, in particular in lung cancer, and for this reason, they may be used as biomarkers of diagnosis and prognosis, as well as in therapies. Likewise, the design of the therapies based on metalloproteins is a growing research area \[[@B116-ijms-20-00778]\]. For instance, the targeting of the zinc finger proteins by miRNAs, which act as a tumor suppressor by reducing cell proliferation, migration, and invasion as well as inducing apoptosis in human glioblastoma cell lines and glioma stem cells \[[@B117-ijms-20-00778]\].

In this sense, there are few works related with the determination of metallobiomolecules in cancer, and even less in relation to lung cancer. In this context, the importance of metallothioneins (MT) in tumor formation, progression, and drug resistance has been proven \[[@B118-ijms-20-00778]\]. For this reason, MTs may provide potential promising markers for cancer. MTs are high-content cysteine proteins, which play critical roles in homeostasis and protection against heavy metals, DNA damage, and oxidative stress, acting as antioxidants against free radicals and oxidative stress. Moreover, MTs control the homeostasis of the Cu/Zn ratio, which is essential in cell proliferation and differentiation \[[@B118-ijms-20-00778]\]. Different isoforms of these metallothioneins (MTs) have been determined in the lung by studying related genes by means of the analysis of the reaction in the polymerase chain with reverse transcriptase (RT-PCR) \[[@B119-ijms-20-00778],[@B120-ijms-20-00778]\]. The down-expression of MTs isoforms (MT1A, MT2A, MT1E, and MT1G), which are related to gene methylation, has been described in lung cancer \[[@B119-ijms-20-00778]\].

On the other hand, the metalloprotein profiles in human plasma have also been described using a flow fractionation system with asymmetric flow field coupled to inductive coupling plasma with mass detector (AF4-ICP-MS). This study demonstrated that the profiles of Mn, Ni, Cu Zn, I, and Ba are different in patients with lung cancer and controls, and several metalloproteins have been identified by coupling nanochromatography and ion trap mass spectrometry with an electrospray ionization source/mass spectrometry \[[@B77-ijms-20-00778]\]. In particular, the Zn metallobiomolecules have been studied in childhood brain tumors \[[@B117-ijms-20-00778]\].

Under our knowledge, the speciation of elements should be performed in samples of LC patients. As discussed before, elements can be mainly present as labile ions or complexed with low molecular mass ligands, or in the form of metalloproteins. In a study of our group, an analytical metallomic approach based on the non-denaturing precipitation of proteins (NDPP) was optimized for the fractionation of high molecular mass (HMM) and low molecular mass (LMM) metal species, in order to distinguish between metal species that affect the biological activity and toxicological potential of the elements \[[@B75-ijms-20-00778]\]. We concluded that several metals are good biomarkers when they are related to the labile ions, complexed with low molecular mass ligands, or in the form of metalloproteins (i.e., V and Cr in HMM and Cu in LMM), which were described for the first time. The analytical methodology was based on the use of an inductively coupled plasma triple quadrupole mass spectrometry (ICP-QQQ-MS), which has not been previously used in biofluids from LC patients \[[@B75-ijms-20-00778]\].

6. Gaps and Future {#sec6-ijms-20-00778}
==================

Significant evidences can be found in the literature in relation to the key role of metals in the onset and progression of cancer, particularly in lung cancer. This open the possibilities of using them as biomarkers of early diagnosis, prognosis, or therapy. However, intense research should be performed in connection with the differentiation between chemical species, metalloproteins, and the interplay of elements on the basis of metals ratios and correlations. The Cu:Zn ratio has been demonstrated to be the best inter-element biomarker for lung cancer diagnosis in the majority of the samples, but recent studies have also demonstrated the importance of V/Mn, V/Pb, V/Zn, and Cr/Pb in serum; Cr/Cd, Mn/Cd, V/Cd, Co/Cd, and Cd/Pb in urine; and V/Cu in BALF, which reflect the dyshomeostasis of metals that takes place in LC. Important significant correlations can be found between elements in LC patients, such as for example between selenium and zinc, which is implicated in glucometabolic disorders, cobalt and copper, and copper and iron, among others. The influence of individual factors (i.e., sex, age, diet, etc.) in the concentration of metals that can be found in biofluids may be the main pitfall regarding the use of metals dyshomeostasis as biomarkers of lung cancer, and effort should be made in this direction to correctly establish a direct cause--effect link.

Powerful analytical techniques can be used for metal identification and quantification, mainly inductively coupled plasma mass spectrometry (ICP-MS) with single or preferably triple quadrupole mass spectrometer equipped with a collision/reaction cell for the elimination of interferences. The selection of the biofluid to be analyzed is critical, as well as the sample preparation procedure to isolate metal-containing fractions (high/low molecular mass fractions) or metallobiomolecules, for instance metalloproteins, of which 50% are influenced by metals.
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###### 

Typical concentrations of metals in biofluids and tissues of lung cancer (LC) patients.

  Element   Sample             Average Concentration (µg·L^−1^)   FC (LC/HC)   *p*            Analytical Technique   Reference                                                       
  --------- ------------------ ---------------------------------- ------------ -------------- ---------------------- ------------------ ----------------- -------------------------- --------------------------
  Ag        Pleural effusion   0.2 \*^,1^                         \-           0.18 \*^,1^    \-                     1.11               N.S.^a^           ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      0.547              0.696                              0.722        1.416          0.76                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Al        Pleural effusion   91.1 \*^,1^                        \-           199.3 \*^,1^   \-                     0.46               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      1879               2405                               12820        4104           0.15                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Hair      16.46              16.31                              11.366       12.685         1.45                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     189.11             58.94                              220.8        147.3          0.86                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  As        Pleural effusion   3.95 \*^,1^                        \-           2.66 \*^,1^    \-                     1.48               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Plasma    2.49               1.35                               2.74         1.91           0.91                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      0.458              1.269                              0.558        0.742          0.82                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Au        Hair               2.744                              6.471        0.687          1.218                  3.99               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  B         Hair               277                                386          1896           953                    0.15               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Plasma    65.79              38.06                              70.13        35.81          0.94                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      1.764              2.058                              1.136        1.915          1.55                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Ba        Hair               96,780                             117,900      156,900        114,800                0.62               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Plasma    7.78               5.98                               6.42         5.07           1.21                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      1.461              1.972                              1.396        1.513          1.05                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Be        Hair               0.012                              0.017        0.038          0.074                  0.32               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  Bi        Hair               0.872                              0.916        0.445          0.718                  1.96               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  Ca        Serum              75,620                             11,140       93,780         6851                   0.81               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Hair      969,300            944,700                            1,215,000    822,200        0.80                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Hair      68.25              61.33                              30.812       18.809         2.22                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Cd        Hair               51                                 48           245            501                    0.21               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Hair      0.209              0.176                              0.316        0.426          0.66                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     10.06              2.66                               6.69         5.11           1.50                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  Serum     0.18 ^1^           0.04                               0.07 ^1^     0.00           2.50                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     1.58 ^1^           0.21                               0.55 ^1^     0.07           2.86                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      0.14 ^1^           0.04                               0.08 ^1^     0.02           1.82                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Ce        Hair               2.724                              8.11         0.958          2.886                  2.84               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  Co        Pleural effusion   0.24 \*^,1^                        \-           0.17 \*^,1^    \-                     1.41               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      33                 36                                 57           47             0.58                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Hair      3.131              11.057                             0.392        0.467          7.99                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Serum     0.46               0.07                               0.27         0.07           1.71                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     0.43               0.02                               0.65         0.05           0.67                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      0.008              0.003                              0.001        0.001          5.60                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Cr        Pleural effusion   1.37 \*^,1^                        \-           0.98 \*^,1^    \-                     1.40               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Serum     1706               1326                               111          164            15.37                  N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Hair      ND                 \-                                 814          401            \-                     N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Plasma    33.4               7.64                               31.47        8.55           1.06                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      2.492              4.021                              0.934        1.016          2.67                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     44.61              14.44                              23.08        20.52          1.93                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  Serum     0.96               0.15                               0.51         0.21           1.89                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     1.90               0.17                               1.91         0.27           0.99                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      0.30               0.07                               0.19         0.04           1.58                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Cs        Hair               0.264                              0.284        0.246          384                    1.07               N.S. ^b^          ICP-MS                     \[[@B73-ijms-20-00778]\]
  Cu        Pleural effusion   850.2 \*^,1^                       \-           910.5 \*^,1^   \-                     0.93               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Serum     1392               278                                929          232            1.50                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Hair      9827               1526                               11,540       1237           0.85                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Plasma    1256.3             214.7                              1007         197.4          1.25                   *p* \< 0.01 ^b^    ICP-MS            \[[@B76-ijms-20-00778]\]   
  Serum     1518.8             69.9                               1264.7       57.2           1.20                   N.S. \*\*          AAS               \[[@B81-ijms-20-00778]\]   
  Hair      24.45              18.47                              15.753       16.73          1.55                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     73.25              24.04                              29.93        21.87          2.45                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  Serum     1455.3             394.01                             953.25       95.325         1.53                   *p*≤0.05 ^b^       AAS               \[[@B82-ijms-20-00778]\]   
  Serum     1428.7             51.5                               1251.1       56.0           1.14                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     20.5               2.0                                15.2         1.8            1.35                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      4.93               0.96                               3.55         1.54           1.39                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Fe        Pleural effusion   747.7 \*^,1^                       \-           1049 \*^,1^    \-                     0.71               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Serum     2168               938                                1988         913            1.09                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Hair      23,100             13,550                             16,180       4619           1.43                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Plasma    1298.2             642.6                              1469.1       514.2          0.88                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      9.65               6.64                               25.052       22.93          0.39                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     309.32             85.05                              310.4        242.1          1.00                   N.S. ^b^           ICP-AES           \[[@B79-ijms-20-00778]\]   
  Serum     6151.7 ^1^         981.3                              2947.9 ^1^   470.8          2.09                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     50.5 ^1^           4.2                                35.5 ^1^     3.6            1.42                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      21.7 ^1^           5.1                                39.8 ^1^     20.1           0.55                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Ga        Hair               0.288                              0.59         0.25           0.23                   1.15               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  Hg        Hair               1.233                              1.367        0.585          0.713                  2.11               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  K         Hair               15.32                              18.66        10.701         9.25                   1.43               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  La        Hair               369                                381          728            372                    0.51               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Li        Hair               0.595                              0.67         571            0.586                  0.00               N.S. ^b^          ICP-MS                     \[[@B73-ijms-20-00778]\]
  Mg        Serum              20,160                             3770         24,580         2655                   0.82               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Hair      77,330             93,220                             141,800      107,900        0.55                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Hair      28.92              24.203                             31.921       21.315         0.91                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Mn        Pleural effusion   0.83 \*^,1^                        \-           0.87 \*^,1^    \-                     0.95               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      2523               1898                               1130         1714           2.23                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Plasma    5.29               5.06                               4.22         2.88           1.25                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      1.82               2.16                               1.144        1.119          1.59                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     4.74               3.23                               6.95         5.43           0.68                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  Serum     1.74 ^1^           0.08                               1.14 ^1^     0.14           1.52                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     3.48 ^1^           0.23                               4.09 ^1^     0.58           0.85                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      0.69 ^1^           0.09                               0.46 ^1^     0.06           1.51                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Mo        Pleural effusion   1.23 \*^,1^                        \-           1.05 \*^,1^    \-                     1.17               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      158                221                                132          75             1.20                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Serum     0.73 ^1^           0.22                               0.43 ^1^     0.06           1.67                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     32.8 ^1^           2.9                                25.8 ^1^     3.5            1.27                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      0.11 ^1^           0.02                               0.09 ^1^     0.02           1.14                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Na        Hair               23.316                             30.458       21.378         15.79                  1.09               N.S. ^b^          ICP-MS                     \[[@B73-ijms-20-00778]\]
  Ni        Hair               117                                168          454            907                    0.26               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Plasma    14.35              11.09                              13.36        9.43           1.07                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      1.126              0.8                                0.58         0.547          1.94                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     59.378             8.21                               21           12.7           2.83                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  P         Hair               176,800                            3,891,000    203,100        44,160                 0.87               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Serum     103,700            17,600                             116,100      32,760         0.89                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Pb        Pleural effusion   0.63 \*^,1^                        \-           1.04 \*^,1^    \-                     0.61               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      2364               2302                               4476         7295           0.53                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Plasma    10.61              5.63                               9.31         5.94           1.14                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      8.577              19.88                              5.09         6.198          1.69                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Serum     1.54 ^1^           0.18                               1.11 ^1^     0.11           1.38                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     7.37 ^1^           0.46                               6.20 ^1^     0.48           1.19                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      0.47 ^1^           0.13                               0.16 ^1^     0.02           2.98                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Rb        Hair               0.47                               0.753        0.251          0.3                    1.87               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  Rh        Hair               0.555                              0.614        0.414          0.486                  1.34               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  Sb        Plasma             4.8                                3.36         5.93           3.55                   0.81               *p* \< 0.05 ^b^   ICP-MS                     \[[@B76-ijms-20-00778]\]
  Hair      0.988              0.77                               0.235        0.344          4.20                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Sc        Hair               0.134                              0.545        0.027          0                      4.96               *p* \< 0.05 ^b^   ICP-MS                     \[[@B73-ijms-20-00778]\]
  Se        Plasma             69.88                              15.88        77.95          17.38                  0.90               *p* \< 0.05 ^b^   ICP-MS                     \[[@B76-ijms-20-00778]\]
  Hair      13.7               19.784                             20.135       21.042         0.68                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     15.026             8.33                               5.36         2.78           2.80                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  Serum     191.9 ^1^          6.6                                187.8 ^1^    5.9            1.02                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     51.6 ^1^           6.4                                36.5 ^1^     4.5            1.42                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      3.54 ^1^           0.58                               3.43 ^1^     0.52           1.03                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Sn        Pleural effusion   0.36 \*^,1^                        \-           0.33 \*^,1^    \-                     1.09               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      33.94              24.72                              21.509       19.48          1.58                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Sr        Serum              753                                209          762            253                    0.99               N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Hair      3037               2663                               4894         3889           0.62                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Plasma    24.4               12.8                               23.9         13.2           1.02                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      1.91               1.914                              1.455        1.68           1.31                   N.S. ^b^           ICP-MS            \[[@B73-ijms-20-00778]\]   
  Ti        Plasma             48.5                               24.5         44.5           30.1                   1.09               N.S. ^b^          ICP-MS                     \[[@B76-ijms-20-00778]\]
  Hair      12.64              19.128                             2.079        4.46           6.08                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  V         Pleural effusion   0.22 \*^,1^                        \-           0.36 \*^,1^    \-                     0.61               N.S. ^a^          ICP-MS                     \[[@B80-ijms-20-00778]\]
  Plasma    3.54               1.23                               3.57         1.18           0.99                   N.S. ^b^           ICP-MS            \[[@B76-ijms-20-00778]\]   
  Hair      1.83               2.29                               1.047        1.74           1.75                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Serum     0.17               0.04                               0.05         0.02           3.77                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     1.34               0.09                               1.31         0.09           1.02                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      1.38               0.03                               1.24         0.04           1.11                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Y         Hair               10                                 33           ND             \-                     \-                 N.SP.             ICP-AES                    \[[@B24-ijms-20-00778]\]
  Zn        Pleural effusion   351.7 \*^,1^                       \-           545.7 \*^,1^   \-                     0.64               *p* \< 0.05 ^a^   ICP-MS                     \[[@B80-ijms-20-00778]\]
  Hair      151,380            37,160                             171,100      41,160         0.88                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Plasma    702.4              129.2                              772.2        191.4          0.91                   *p* \< 0.01 ^b^    ICP-MS            \[[@B76-ijms-20-00778]\]   
  Serum     836.87             45.77                              934.93       84.99          0.90                   N.S. \*\*          AAS               \[[@B81-ijms-20-00778]\]   
  Hair      53.22              60.3                               109.763      95.33          0.48                   *p* \< 0.05 ^b^    ICP-MS            \[[@B73-ijms-20-00778]\]   
  Urine     1519.8             194.8                              568.9        544.7          2.67                   *p* \< 0.01 ^b^    ICP-AES           \[[@B79-ijms-20-00778]\]   
  Serum     1136.4             67.0                               917.5 ^1^    75.5           1.24                   *p* \< 0.05 ^c^    ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Urine     637.0              89.7                               572.3 ^1^    115.1          1.11                   N.S. ^c^           ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  BALF      35.1               13.4                               15.0 ^1^     5.7            2.33                   *p* \< 0.05. ^c^   ICP-QQQ-MS        \[[@B75-ijms-20-00778]\]   
  Serum     29                 12                                 33           14             0.88                   N.SP.              ICP-AES           \[[@B24-ijms-20-00778]\]   
  Serum     784.56             130.36                             902.24       130.76         0.87                   *p* ≤ 0.05 ^b^     AAS               \[[@B82-ijms-20-00778]\]   

BALF: Bronchoalveolar Lavage Fluid; LC: Lung Cancer; HC: Healthy Control; ND: Not Detected; SD: Standard Deviation; FC: Fold Change. N.S.: Non significant, N.SP.: Not specified. Average Concentration: Arithmetic Mean, Gaussian Distribution, \* Data expressed on the median.; ^1^: Non-parametric method; ^a^: Kruskal--Wallis test; ^b^: Student T-test; ^c^: Mann--Whitey U-test; \*\* Statistical test not specified.
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###### 

Significant correlations between elements in the biofluids and tissues of lung cancer patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       P   S                                 Ti   Cr                                Se                                Mn                                 Fe                                 Hg                                V                                Zn                               Pb                               Cu                              Co                              Mo
  ---- --- --------------------------------- ---- --------------------------------- --------------------------------- ---------------------------------- ---------------------------------- --------------------------------- -------------------------------- -------------------------------- -------------------------------- ------------------------------- ------------------------------- -------------------------------
  P        Tissue \[[@B72-ijms-20-00778]\]                                                                                                                                                                                                                                                                                                                                                       

  S                                                                                                                                                                                                                                                                                                                                                                                              

  Ti                                              Tissue \[[@B72-ijms-20-00778]\]   Tissue \[[@B72-ijms-20-00778]\]                                                                                                                                                                                                                                                                              

  Cr                                                                                BALF \[[@B75-ijms-20-00778]\]     Tissue \[[@B72-ijms-20-00778]\]\                                                                        Serum \[[@B75-ijms-20-00778]\]   BALF \[[@B75-ijms-20-00778]\]                                                                                                     
                                                                                                                      Hair \[[@B73-ijms-20-00778]\]\                                                                                                                                                                                                                                             
                                                                                                                      Urine \[[@B75-ijms-20-00778]\]                                                                                                                                                                                                                                             

  Se                                                                                                                                                                                        Tissue \[[@B72-ijms-20-00778]\]                                    BALF \[[@B75-ijms-20-00778]\]                                                                                                     

  Mn                                                                                                                                                     Tissue \[[@B72-ijms-20-00778]\]\                                                                      Serum \[[@B75-ijms-20-00778]\]                                    BALF \[[@B75-ijms-20-00778]\]                                   
                                                                                                                                                         Urine \[[@B75-ijms-20-00778]\]                                                                                                                                                                                                          

  Fe                                                                                                                                                                                                                                                                                            Urine \[[@B75-ijms-20-00778]\]                                                                   

  Hg                                                                                                                                                                                                                                                                                                                                                                                             

  V                                                                                                                                                                                                                                                                                             BALF \[[@B75-ijms-20-00778]\]                                                                    

  Zn                                                                                                                                                                                                                                                                                                                                                                                             

  Pb                                                                                                                                                                                                                                                                                                                                                                                             

  Cu                                                                                                                                                                                                                                                                                                                                                             BALF \[[@B75-ijms-20-00778]\]   

  Co                                                                                                                                                                                                                                                                                                                                                                                             BALF \[[@B75-ijms-20-00778]\]

  Mo                                                                                                                                                                                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BALF: Bronchoalveolar Lavage Fluid.
